What are the clinical indications for antiplatelet therapy?

Indications for Antiplatelet Therapy

Antiplatelet therapy is indicated for secondary prevention in patients with established atherosclerotic cardiovascular disease, including those with coronary artery disease, cerebrovascular disease, and peripheral artery disease, to reduce the risk of myocardial infarction, stroke, and vascular death. 1, 2, 3

Secondary Prevention - Established Cardiovascular Disease

Coronary Artery Disease

Post-Acute Coronary Syndrome (ACS):

• Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is mandatory for 12 months following ACS 4, 5
• Preferred P2Y12 inhibitors: ticagrelor or prasugrel over clopidogrel (stronger platelet inhibition) 5
• Clopidogrel 75 mg daily is acceptable if ticagrelor or prasugrel are contraindicated 5
• After 12 months, continue single antiplatelet therapy (aspirin 75-162 mg daily) indefinitely 4

Post-Percutaneous Coronary Intervention (PCI):

• Drug-eluting stents: DAPT for 12 months minimum 4
• Bare metal stents: DAPT for at least 1 month 4
• After completing DAPT duration, continue single antiplatelet therapy indefinitely 4

Stable Coronary Artery Disease:

• Single antiplatelet therapy with aspirin 75-325 mg daily or clopidogrel 75 mg daily 4, 3
• Clopidogrel demonstrated superiority over aspirin in the CAPRIE trial for reducing combined vascular events 2, 3

Cerebrovascular Disease

Post-Stroke or TIA (Non-Cardioembolic):

• For minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4): Start DAPT immediately 1

  • Aspirin 81 mg + clopidogrel 75 mg daily
  • Loading doses: aspirin 160-325 mg + clopidogrel 300-600 mg
  • Continue DAPT for 21 days, then switch to single antiplatelet therapy 1

• Alternative regimen: Aspirin 75-100 mg + ticagrelor 90 mg twice daily 1

  • Loading doses: aspirin 300-325 mg + ticagrelor 180 mg
  • Continue for 30 days, then single antiplatelet therapy 1

• For chronic secondary prevention: Single antiplatelet therapy with aspirin, clopidogrel, or aspirin-dipyridamole combination 1, 5

Critical caveat: Anticoagulation is not superior to antiplatelet therapy for non-cardioembolic stroke and is not recommended 5

Peripheral Artery Disease (PAD)

Symptomatic PAD:

• Single antiplatelet therapy is the standard 2, 3, 4
• Clopidogrel 75 mg daily preferred over aspirin (superior efficacy in CAPRIE trial) 2, 3
• Aspirin 75-325 mg daily is an acceptable alternative 3, 4

Post-Revascularization (Endovascular or Surgical):

• Continue single antiplatelet therapy long-term 2, 4
• After surgical revascularization with prosthetic graft: Consider DAPT for at least 1 month 2
• For infrainguinal grafts at high risk of thrombosis: May consider warfarin plus aspirin 4

Enhanced Regimen for High-Risk PAD:

• Rivaroxaban 2.5 mg twice daily plus aspirin 75-100 mg daily reduces major adverse cardiovascular and limb events 2
• This comes with increased major bleeding risk—reserve for patients with symptomatic PAD at high ischemic risk and acceptable bleeding risk 2

Important: Full-dose oral anticoagulation without another indication (e.g., atrial fibrillation) should NOT be used in PAD—it may be harmful 2

Intracranial Atherosclerotic Stenosis

For moderate to high-grade stenosis (50-99%):

• DAPT is appropriate medical therapy 1
• Combine with blood pressure control (target <140 mmHg systolic) and high-dose statin 1
• Angioplasty and stenting are NOT recommended 1

Primary Prevention - No Established Cardiovascular Disease

Aspirin for primary prevention cannot be recommended due to increased bleeding risk that offsets potential ischemic benefit 4, 5. The evidence shows:

• Only marginal reduction in vascular events (0.57% to 0.51% per year) 5
• No significant net benefit on stroke 5
• Increased risk of major bleeding 4, 5

Exception: In highly selected individuals with multiple atherosclerotic risk factors and low bleeding risk, aspirin 75-162 mg daily may be considered, but this is not a routine recommendation 4

Special Populations

Diabetes Mellitus

• Diabetes alone should not dictate DAPT duration or selection 6
• Follow standard indications based on underlying cardiovascular disease 6

Lower Extremity Artery Disease with CAD

• Patients with both LEAD and CAD have exceptionally high ischemic risk 6
• In post-MI patients with LEAD, ticagrelor 60 mg twice daily showed 5.2% absolute risk reduction at 3 years 6
• Prolonged DAPT may be beneficial in this high-risk subset 6

Asymptomatic PAD (ABI ≤0.90)

• Antiplatelet therapy benefit is uncertain 2, 3
• The 2011 ACC/AHA guidelines removed the previous recommendation for antiplatelet therapy in asymptomatic PAD 3

Key Dosing Recommendations

Aspirin:

• Acute loading: 160-325 mg 1, 5
• Maintenance: 75-100 mg daily (preferred low-dose) 1, 2, 5
• Maximum 325 mg daily for chronic use 3

Clopidogrel:

• Loading: 300-600 mg 1, 4
• Maintenance: 75 mg daily 1, 4, 3

Ticagrelor:

• Loading: 180 mg 1, 5
• Maintenance: 90 mg twice daily 1, 5
• For extended therapy post-MI: 60 mg twice daily 6

Common Pitfalls to Avoid

1. Do not use DAPT for primary prevention—bleeding risk exceeds benefit
2. Do not continue DAPT beyond indicated duration without specific high-risk features—increases bleeding without additional benefit
3. Do not use full-dose anticoagulation in PAD without another indication (e.g., atrial fibrillation)—it is harmful 2
4. Do not add antiplatelet therapy to therapeutic anticoagulation for atrial fibrillation unless there is a specific indication like recent ACS or stent 7
5. Do not use aspirin doses >100 mg when combining with anticoagulation—increases bleeding risk 7